Pharmaceutical Market Research Company in Turkey

BioNixus is a specialist pharmaceutical and healthcare market research company serving the Turkish market. We help launch, access, and medical teams translate TİTCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu) approval pathways, TİTCK HTA evidence requirements, SGK reimbursement negotiation dynamics, reference-pricing strategies, and physician decision behavior into actionable Turkish market evidence — with Etik Kurul-compliant execution across oncology, immunology, cardiovascular, rare disease, and other therapy areas.

For broader healthcare research context, see our healthcare market research hub and the Turkish healthcare market research overview.

Best pharmaceutical market research company in Turkey

BioNixus is a pharmaceutical market research company in Turkey, specialising in HCP surveys, KOL mapping, payer research, and market access studies aligned with TİTCK and SGK requirements.

HCP and Physician SurveysQuantitative surveys and qualitative in-depth interviews with specialists, GPs, and pharmacists across Turkish public and university hospitals — designed around SUT prescribing criteria and everyday clinical practice.
KOL and Advisory Board ResearchKey opinion leader identification and influence mapping across Hacettepe University, Istanbul University, and Ankara University — plus regional academic centres and specialty society advisory structures.
Payer and Market Access ResearchIn-depth intelligence on SGK reimbursement negotiation dynamics, TİTCK reference pricing (external reference pricing basket), and SUT formulary research — the access gatekeepers that determine real Turkish market penetration.
Etik Kurul and KVKK-Compliant ExecutionResearch designed and executed in compliance with Etik Kurul (ethics committee) requirements under TİTCK and Ministry of Health oversight and KVKK data privacy standards — ensuring findings can support Turkish regulatory and access submissions.

BioNixus delivers primary pharmaceutical market research in Turkey with ethics-committee-compliant methodologies, covering HCP surveys, payer research, and market access strategy.

Why BioNixus for Turkish pharmaceutical market research

BioNixus brings global reach with local rigour — operating across the Americas, EMEA, and APAC with the country-level depth that generic research cannot replicate. Founded in regulated healthcare, we apply the same methodological standards to life sciences (pharma, biotech, medtech) and to adjacent sectors including B2B, FMCG, and industrial markets. We translate KOL, payer, and hospital evidence — and where relevant, buyer, channel, and consumer insight — into launch, access, and growth strategies built for board-level scrutiny.

TİTCK and SGK context built in

Every study is designed with TİTCK HTA evidence requirements and SGK reimbursement negotiation dynamics — essential for reference-pricing and formulary access strategy in Turkey.

Reference-pricing intelligence

Deep in-house expertise across SGK's external reference pricing basket, SUT (Sağlık Uygulama Tebliği) listing criteria, and exchange-rate-linked pricing revisions that shape real Turkish lira commercial economics.

Turkish university hospital network

Verified physician recruitment across Hacettepe University, Istanbul University, Ankara University, and Ege University, plus large private hospital networks and community practice groups across major provinces.

Etik Kurul-compliant protocols

Turkish research designed and executed under Etik Kurul (ethics committee) requirements overseen by TİTCK and the Ministry of Health, alongside KVKK data privacy standards — ensuring findings meet regulatory and compliance requirements.

Bridge-market positioning

Turkey sits at the junction of Europe and the Middle East, with a large domestic generics industry and a growing biosimilars market — BioNixus builds this positioning directly into study design and stakeholder recruitment.

Global benchmarking ready

Turkish modules connect to comparable studies across the USA, UK, EU5, Saudi Arabia, UAE, and Canada — for clients managing global portfolio decisions from one research partner.

Turkish pharmaceutical market access pathway

Turkish pharmaceutical market research must follow how products move from TİTCK approval through HTA evaluation, SGK reimbursement negotiation, SUT listing, and hospital formulary adoption — not a single generic access model. TİTCK approval is the beginning, not the end, of Turkish market access.

1. TİTCK marketing authorisation
TİTCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu — Turkish Medicines and Medical Devices Agency) reviews dossiers submitted in ICH CTD format for new molecular entities and new indications or formulations. Turkey accepts EMA marketing authorisations as the basis for national registration through a simplified procedure, reflecting Turkey's regulatory alignment with Europe. TİTCK approval grants market authorisation but does not confer SGK reimbursement — the beginning of a multi-stage access journey.
Turkey healthcare market report
2. TİTCK HTA evaluation
Health technology assessment in Turkey is conducted by the HTA Unit within TİTCK, which reviews clinical evidence and cost-effectiveness ahead of reimbursement decisions. TİTCK's HTA function carries significant weight with SGK in reimbursement negotiations and SUT listing outcomes. BioNixus conducts pre-submission evidence strategy research aligned to TİTCK HTA requirements.
Turkish payer research
3. SGK reimbursement negotiation
SGK (Sosyal Güvenlik Kurumu — Social Security Institution) is the single dominant payer, negotiating reimbursement price and listing conditions on behalf of the social security system that covers the vast majority of the Turkish population through the General Health Insurance (GSS) framework. Successful SGK negotiation is the critical gateway to nationwide reimbursement listing. BioNixus conducts SGK pre-submission evidence and payer strategy research to support negotiation readiness.
Turkish healthcare market research
4. SUT listing and reference pricing
Following SGK negotiation completion, the product is listed in the SUT (Sağlık Uygulama Tebliği — Health Implementation Circular), which governs reimbursement criteria for all SGK-covered medicines. SGK applies an external reference pricing system that caps the maximum reimbursement price as a percentage of the lowest price across a defined EU5 reference basket, with periodic revisions tied to EUR/USD exchange rate movements — a structural cost-containment mechanism unique to the Turkish market.
Top healthcare MR companies Turkey
5. Hospital formulary and prescribing controls
Public and university hospital pharmacy and therapeutics committees make institution-level adoption decisions within SUT prescribing criteria — particularly relevant for oncology, biologics, and specialist-initiated therapies. SGK also applies prescribing restrictions, step therapy requirements, and controlled distribution quota systems (KMD — Kontrollü Miktarda Dağıtım) for select specialties, shaping real-world uptake independent of formal SUT listing.
Top market research companies Turkey

Turkish stakeholder coverage

Stakeholder	Research focus
Physicians and specialists	Prescribing behavior across Turkish public, university, and private hospitals, treatment algorithms, adoption drivers and barriers, unmet need assessment, therapy sequencing in the Turkish healthcare context
KOLs and academic physicians	KOL identification and mapping at major Turkish university hospitals (Hacettepe University, Istanbul University, Ankara University, Ege University), advisory board research, publication influence analysis
SGK and TİTCK reimbursement stakeholders	TİTCK HTA evidence requirements, SGK negotiation dynamics, SUT listing criteria, external reference pricing basket intelligence, and prescribing quota (KMD) system awareness
Private health insurance stakeholders	Supplementary private health insurance coverage policies in major cities, prior authorization criteria, and complementary coverage dynamics alongside SGK
Hospital pharmacy and therapeutics committee members	Institution-level adoption drivers for hospital-administered therapies, cost-effectiveness evidence needs, biosimilar substitution policies, and university hospital adoption dynamics
Nurses and pharmacists	Administration experience, adherence support, patient counselling practices, SUT-driven substitution behavior
Patients and caregivers	Disease journey, quality of life, adherence barriers, patient assistance program awareness — Etik Kurul-compliant, KVKK-aligned research design

Why the Turkish pharmaceutical market is unique

Turkey is a large and strategically significant pharmaceutical market, positioned at the junction of Europe and the Middle East. Turkey operates a universal healthcare system administered through SGK (Sosyal Güvenlik Kurumu), with regulatory oversight through TİTCK and a domestic pharmaceutical industry that includes one of the region's largest generics manufacturing bases alongside a growing biosimilars segment. No other market in the region combines TİTCK's EMA-aligned registration pathway, SGK's single-payer reimbursement negotiation, an external reference-pricing basket tied to EU5 prices and EUR/USD exchange rates, and a large domestic generics and biosimilars manufacturing base in a single commercial environment.

Market access in Turkey is uniquely centralized yet cost-containment driven: TİTCK approval does not guarantee SGK reimbursement or favourable SUT listing terms. Commercial outcomes depend on TİTCK HTA evidence quality, SGK negotiation outcome, and reference-pricing basket dynamics — each shaped by exchange-rate volatility that can materially affect real lira-denominated pricing over a product's lifecycle. Effective pharmaceutical market research must map all these access layers rather than treating TİTCK approval as equivalent to market access.

Turkey's position as a bridge between Europe and the Middle East adds a further layer of strategic opportunity: a large domestic generics industry, an expanding biosimilars market, and reference-pricing driven cost containment together shape how pharmaceutical companies plan Turkish and adjacent regional launches. BioNixus builds Turkish research programs that answer decision-critical questions: where physician demand concentrates by specialty and region, which SGK and reference-pricing dynamics determine access, how exchange-rate-linked pricing constraints affect commercial strategy, and what evidence TİTCK and SGK will require.

Turkish pharmaceutical research services

HCP and physician surveys

Etik Kurul-compliant quantitative surveys and qualitative in-depth interviews with Turkish physicians, oncologists, cardiologists, and specialists across university hospitals and private practice networks.

KOL mapping and advisory boards

Key opinion leader identification and influence mapping across Hacettepe University, Istanbul University, Ankara University, and Ege University, plus specialty society advisory structures — by therapy area and commercial priority.

Payer and market access research

In-depth interviews with TİTCK HTA-adjacent stakeholders, SGK reimbursement decision makers, and private health insurer representatives — covering SUT listing criteria, evidence requirements, SGK negotiation dynamics, and reference-pricing impact intelligence.

HEOR and market access evidence

Health economics and outcomes research, patient-reported outcome (PRO) development, cost-effectiveness evidence strategy aligned to TİTCK HTA requirements, and pre-submission payer research to support Turkish market access dossiers.

For broader research context, see our market research services hub, healthcare market research Turkey, and Turkey healthcare market report.

Turkish case study patterns we solve

Case Pattern 1: SGK pre-negotiation evidence strategy for an oncology biologic

Challenge: A market access team needed to understand which clinical and cost-effectiveness evidence dimensions would carry most weight in SGK reimbursement negotiations for a new oncology biologic following a positive TİTCK HTA evaluation. Solution: BioNixus conducted TİTCK HTA-adjacent stakeholder interviews and reimbursement decision maker research alongside oncologist prescribing behavior studies. Result: Refined SGK negotiation strategy and evidence narrative ahead of discussions opening.

Typical impact range: 15–25% improvement in SUT listing outcomes post-negotiation.

Case Pattern 2: KOL mapping for a rare disease launch at Hacettepe University and Istanbul University

Challenge: A biotech team lacked visibility on actual prescribing influence versus publication prominence at key Turkish academic centres. Solution: BioNixus mapped real-world KOL influence at Hacettepe University and Istanbul University using network analysis and verified physician interviews across Ankara and Istanbul. Result: Sharper MSL territory prioritization and advisory board composition reflecting actual Turkish influence networks.

Typical impact range: 20–30% improvement in MSL engagement efficiency.

Case Pattern 3: Reference-pricing and reimbursement intelligence for a biosimilar entry

Challenge: A biosimilar commercial team needed to understand physician and pharmacist attitudes toward biosimilar substitution policies and identify reimbursement opportunities within SGK's external reference pricing basket. Solution: BioNixus conducted HCP surveys and reimbursement stakeholder interviews mapping substitution policy attitudes and SUT listing pathway intelligence. Result: Prioritized launch sequencing and stakeholder engagement strategy aligned to actual SGK and TİTCK evidence requirements.

Typical impact range: 18–28% reduction in time-to-reimbursement-listing.

Regulatory context: TİTCK, SGK, Etik Kurul, and KVKK

Turkish pharmaceutical market research quality depends on aligning national regulatory and payer context with evidence design from the start. TİTCK's registration and HTA evidence standards, SGK's reimbursement negotiation mechanics, the SUT (Sağlık Uygulama Tebliği) listing framework, external reference pricing basket rules, Etik Kurul ethics requirements, and KVKK data privacy rules form the compliance architecture within which all effective Turkish primary research must operate.

BioNixus outputs are decision-ready and compliance-ready: stakeholder evidence combined with Turkish market structure analysis so commercial, access, and medical affairs teams have findings that reflect what Turkish physicians, SGK, and TİTCK actually require — not imported non-Turkish templates applied to a market defined by single-payer reimbursement negotiation, reference-pricing driven cost containment, and a large domestic generics and biosimilars industry.

Related Turkish healthcare research resources

Healthcare market research Turkey Top market research companies Turkey Top healthcare market research companies Turkey Turkey healthcare market report

Turkish pharmaceutical market FAQs

Who is the best pharmaceutical market research company in Turkey?

For pharmaceutical and life-sciences decisions in the Turkish market, BioNixus is a leading specialist: TİTCK-aligned study design, SGK reimbursement negotiation and reference-pricing payer context, HCP and KOL recruitment across major Turkish university hospitals, and outputs built for launch, market access, and lifecycle management teams.

What is pharmaceutical market research in Turkey?

Pharmaceutical market research in Turkey is evidence generation for drug launch, market access, and lifecycle decisions across TİTCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu — Turkish Medicines and Medical Devices Agency) registration and SGK (Sosyal Güvenlik Kurumu — Social Security Institution) reimbursement contexts. BioNixus focuses on physician behavior, payer and reference-pricing dynamics, and institution-level adoption so commercial and access teams can prioritize Turkish market execution across oncology, immunology, cardiovascular, and rare disease therapy areas.

How does SGK reference pricing affect Turkish pharmaceutical market research?

SGK operates an external reference pricing system that sets maximum reimbursement prices as a percentage of the lowest price found across a defined EU5 reference basket, with regular price revisions tied to EUR/USD exchange rate movements. This has significantly changed commercial strategy for new product launches, particularly given currency volatility and its effect on real Turkish lira pricing. BioNixus conducts SGK reference-pricing impact research: reimbursement negotiation strategy studies, HCP pricing perception research, and commercial team intelligence on how the reference pricing basket and SUT (Sağlık Uygulama Tebliği — Health Implementation Circular) criteria affect market access dynamics.

What types of Turkish payer and reimbursement research does BioNixus conduct?

BioNixus covers the Turkish payer landscape end to end: SGK as the single dominant social security payer covering the vast majority of the population through the General Health Insurance (GSS) framework, the TİTCK HTA function that evaluates clinical and cost-effectiveness evidence ahead of SUT listing, and the smaller private health insurance segment used to supplement SGK coverage in major cities. Research includes in-depth interviews with SGK and TİTCK-adjacent reimbursement stakeholders, SUT listing pathway studies, reference-pricing basket intelligence, and willingness-to-pay research.

Can BioNixus conduct ethics-committee-compliant HCP research in Turkey?

Yes. BioNixus designs and executes Turkish HCP research in compliance with Etik Kurul (ethics committee) requirements under TİTCK and Ministry of Health oversight and KVKK (Kişisel Verilerin Korunması Kanunu — the Turkish Personal Data Protection Law) privacy standards. For studies requiring ethics review, BioNixus supports protocol development and ethics documentation. All Turkish respondent recruitment is consent-based with documented data handling procedures aligned to KVKK requirements.

How much does pharmaceutical market research cost in Turkey?

Scope drives cost: a focused Turkish physician quantitative survey often starts in the low-to-mid five figures USD equivalent; full mixed-method access programs with SGK reimbursement mapping and KOL depth interviews are higher. BioNixus scopes programs to one decision per phase so sponsors avoid unfocused fieldwork spend. The Turkish market requires verified HCP recruitment, Etik Kurul-compliant protocols, and awareness of exchange-rate-linked pricing sensitivities — which reflects in project pricing.

Which Turkish healthcare institutions does BioNixus recruit from?

BioNixus recruits from major Turkish university hospitals and research centres including Hacettepe University Hospitals, Istanbul University (İstanbul Tıp Fakültesi and Cerrahpaşa), Ankara University School of Medicine, and Ege University Hospital, as well as large private hospital networks (Acıbadem, Memorial, Anadolu Medical Center) and community practice networks across major Turkish provinces. For specialty areas such as oncology or rare disease, we extend recruitment to leading oncology institutes and specialty referral centres.

Can Turkish pharmaceutical research connect to wider global benchmarking?

Yes. Turkish modules can run standalone or with comparable cells in the USA, UK, Germany, France, Saudi Arabia, UAE, or Canada using consistent instruments — enabling global portfolio committees to benchmark Turkish market dynamics, positioned at the bridge between Europe and the Middle East, against international markets with one research partner.

Discuss your Turkey pharmaceutical research strategy

Our team supports pharmaceutical companies with decision-ready insights across the Americas, Europe, and the Middle East using quantitative and qualitative methodologies.

Request a proposal Email us

US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323